<DOC>
	<DOCNO>NCT01760291</DOCNO>
	<brief_summary>To provide additional information safety efficacy WATCHMAN LAA Closure Technology</brief_summary>
	<brief_title>Continued Access PREVAIL ( CAP2 )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>A subject may enrol study follow inclusion criterion meet : 1 . The subject 18 year age old 2 . The subject document paroxysmal , persistent , permanent non valvular atrial fibrillation ( i.e. , subject diagnose rheumatic mitral valvular heart disease ) 3 . The subject eligible longterm warfarin therapy 4 . The subject calculate CHADS2 score 2 great ; Subjects CHADS2 score 1 may include follow apply ( accord ACC/AHA/ESC 2006 Guidelines Management Subjects Atrial Fibrillation subject require warfarin therapy ) : The subject female age 75 old The subject baseline Left Ventricular Ejection Fraction ( LVEF ) &gt; 30 % &lt; 35 % The subject age 6574 diabetes coronary artery disease The subject age 65 great document congestive heart failure 5 . The subject legal representative able understand willing provide write informed consent participate trial 6 . The subject able willing return require followup visit examination Subjects exclude study meet follow criterion : 1 . The subject require longterm warfarin therapy ( i.e. , even device implant , subject would eligible discontinue warfarin due medical condition require chronic warfarin therapy ) . Additionally , subject follow exclude : Thrombosis occur young age ( &lt; 40 year old ) Idiopathic recurrent venous thromboembolism Thrombosis unusual site ( i.e. , cerebral vein , hepatic vein , renal vein , inferior vena cava , mesenteric vein ) Family history venous thromboembolism inherit prothrombotic disorder Recurrence extension thrombosis adequately anticoagulated 2 . The subject contraindicate warfarin therapy tolerate longterm warfarin therapy 3 . The subject contraindicate allergic aspirin 4 . The subject indicate antiplatelet therapy aspirin ( example , subject indicate clopidogrel , prasugrel , ticlopidine ticagrelor due DES exclude enrollment dose regimen ) . A subject completing course antiplatelet therapy may enrol 7 day washout period 5 . The subject interventional surgical procedure within 30 day prior enrollment plan interventional surgical procedure time WATCHMAN device implant 45day TEE ( e.g. , cardioversion , ablation , cataract surgery , dental surgery ) 6 . The subject prior stroke TIA within 90 day prior enrollment 7 . The subject MI within 90 day prior enrollment 8 . The subject history atrial septal repair ASD/PFO device 9 . The subject implant mechanical valve prosthesis 10 . The subject suffer New York Heart Association Class IV Congestive Heart Failure time enrollment 11 . The subject symptomatic carotid disease ( define &gt; 50 % stenosis symptoms ipsilateral transient visual TIA evidence amaurosis fugax , ipsilateral hemispheric TIAs ipsilateral stroke ) ; subject history carotid stent endarterectomy subject eligible &lt; 50 % stenosis 12 . The subject 's AF define single occurrence AF 13 . The subject transient case AF ( i.e. , secondary CABG , interventional procedure , etc . ) 14 . The subject 's left atrial appendage obliterate 15 . The subject undergone heart transplantation 16 . The subject currently treat antibiotic active infection 17 . The subject rest heart rate &gt; 110 bpm 18 . The subject thrombocytopenia ( define &lt; 70,000 platelets/mm3 ) anemia hemoglobin concentration &lt; 10 g/dl ( i.e. , anemia determine investigator would require transfusion ) 19 . The subject actively enrol concurrent clinical study investigational drug investigational device ( study specific may review sponsor prior enrollment confirm concurrent study interfere outcomes study ) 20 . The subject participate follow study : PROTECT AF , CAP Registry , PREVAIL . If subject receive subject ID number prior WATCHMAN study , subject may enrol . PROTECT AF control subject may consider participation complete 5 year follow 21 . The subject pregnant pregnancy plan course investigation 22 . The subject life expectancy less two year 23 . The subject unable complete followup visit duration study Echo Exclusion Criteria A subject exclude study follow echocardiographic exclusion criterion ( assessed via TTE TEE ) meet : 1 . The subject LVEF &lt; 30 % 2 . The subject intracardiac thrombus dense spontaneous echo contrast visualized TEE determine echocardiographer within 2 day prior implant 3 . The subject exist pericardial effusion &gt; 2mm 4 . The subject high risk patent foramen ovale ( PFO ) atrial septal aneurysm excursion &gt; 15mm length &gt; 15mm 5 . The subject high risk PFO large shunt define early , within 3 beat substantial passage bubble 6 . The subject significant mitral valve stenosis ( i.e. , MV &lt; 1.5 cm2 ) 7 . The subject complex atheroma mobile plaque descend aorta aortic arch 8 . The subject cardiac tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>